LIVECAST Markets Briefs Calendar Search

Research

AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Briefs Calendar Search AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive Account

Live News NEWS FLASH L impact Sep 22, 2026, 04:02 PM UTC

ENOV - Enovis becomes first multi-registry industry sponsor of AAOS Registry Program

SquawkNews Newsroom

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

ENOV

Related stories

South Korea's Kospi Opens 0.7% Lower at 6844.41 L impact | NEWS | Sep 29, 2026, 12:02 AM UTC New Zealand forecasts smaller deficit as economy grows By Lucy CraymerNew Zealand's government on Tuesday forecast a smaller budget deficit and lower debt than projected in its May Budget, while striking an upbeat tone on economic grow L impact | NEWS | Sep 29, 2026, 12:02 AM UTC ITC Properties Group targets Guangzhou Chaog! Xiyang Technology L impact | NEWS | Sep 29, 2026, 12:02 AM UTC Ihi Corporation - Notice Regarding The Transfer Of Equity Interests Of Steinmueller Engineering GmbH IHI Corporation TSE:7013 L impact | NEWS | Sep 29, 2026, 12:01 AM UTC Ascletis Pharma Inc. Reports Positive 28-Day ASC50 POC Data Ascletis reported a 48.9% placebo-adjusted PASI reduction after 28 days of once-daily 200 mg ASC50 in mild-to-moderate plaque psoriasis, with a 6.5-day half-life and mild AEs. PASI L impact | NEWS | Sep 29, 2026, 12:01 AM UTC Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis 48.9% placebo-adjusted reduction in psoriasis area and severity index (PASI) score achieved in mild-to-moderate plaque psoriasis patients with once-daily 200 mg 28-day treatment. L impact | NEWS | Sep 29, 2026, 12:00 AM UTC

SQUAWK/NEWS

Live financial news for traders. Read the headline on screen or hear it through LiveCast while you stay on the trade.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

Product

Open LiveCast
Plans & Pricing
Institutional API
How LiveCast Works
Live Markets
Session Briefs
RSS Feed
Calendar
Search
Instrument directory

Research

Macro
Politics
Prediction Markets
AI Market Assistant
News Archive

For Traders

Market Movers
US Stocks
Why News Moves Markets
News for Traders
How to Trade the News
What Is an Audio Squawk?
Policy Calendar

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

Legal

Privacy Policy
Terms of Use

© 2026 SquawkNews SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.